AUS
NZ
UK
CA
USA
IND
Highlights
- Actinogen Medical receives a $9 million R&D tax rebate.
- Funds support Alzheimer’s therapy trial with 220 participants.
- Financial backing ensures operations through mid-2026.
Actinogen Medical Ltd (ASX:ACW) has recently received a substantial R&D tax incentive rebate of $9 million for the fiscal year 2024. This rebate is directly linked to Actinogen’s research efforts centered around its leading therapeutic compound, Xanamem, which is undergoing clinical trials as a potential treatment for Alzheimer's disease and Depression.
This rebate, totaling precisely $9,034,351, comes from a Federal government program designed to support companies engaged in research and development by offering cash refunds for eligible R&D expenditures. For Actinogen, this funding injection, combined with existing financial reserves, is a significant boost, ensuring financial support until at least mid-2026. This financial stability allows Actinogen to continue with its critical work, including full enrollment in its Alzheimer’s phase 2b/3 clinical trial, which aims to recruit 220 participants.
Xanamem, Actinogen’s primary focus, represents a novel approach in treating neurological and neuropsychiatric diseases linked to dysregulated cortisol levels in the brain. This therapeutic compound works by targeting and inhibiting the cortisol synthesis enzyme, 11β-HSD1, which regulates cortisol without disrupting its production by the adrenal glands. This unique mechanism addresses cortisol imbalances without impacting other hormone processes, distinguishing Xanamem from other treatments in the field.
The drug is designed for brain access by being absorbed in the intestines before entering the brain, allowing it to deliver its therapeutic effects where needed most. Actinogen sees Xanamem as a promising solution to neurological conditions like Alzheimer’s and Depression, providing new avenues of hope for patients who have few effective treatment options.
Following the announcement of the R&D rebate, Actinogen’s share price reflected positive market sentiment, with shares rising to 2.5 cents, marking an increase of 4.17% by 13:33 AEDT. This response highlights investor confidence in the potential of Actinogen's work on Xanamem and the company’s strategic focus on advancing this innovative treatment.
With this significant funding support, Actinogen is well-positioned to make substantial progress in its clinical trials and advance its mission to develop impactful therapies for complex neurological diseases.
